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Abstract: Transition metals have been successfully applied to 
catalyze non-natural chemical transformations within living cells, with 
the highly efficient labelling of subcellular components and the 
activation of prodrugs. In vivo applications, however, have been 
scarce, with a need for the specific cellular targeting of the active 
transition metals. Here, we show the design and application of 
cancer-targeting palladium catalysts, with their specific uptake in 
brain cancer (glioblastoma) cells, while maintaining their catalytic 
activity. In these cells, for the first time, two different anticancer 
agents were synthesized simultaneously intracellularly, by two totally 
different mechanisms (in situ synthesis and decaging), significantly 
enhancing the therapeutic effect of the drugs. Tumor specificity of 
the catalysts together with their ability to perform simultaneous 
multiple bioorthogonal transformations will empower the application 
of in vivo transition metals for drug activation strategies. 
Bioorthogonal reactions have been explored and tuned over the 
past 20 years to allow them to be successfully applied in an 
array of cellular manipulations.[1–6] However, reaction conditions 
within the biological milieu are challenging and only a handful of 
such chemical reactions are viable under these demanding 
conditions. Although the use of transition metal catalysis within 
living systems is non-trivial, due to stability, efficiency and 
potential poisoning of the catalysts, it has gained importance 
with many successes over the past few years.[7–13] Palladium 
mediated transformations, especially, have been employed 
successfully in a number of biological settings, including protein 
modifications and activations.[8,14–18] These transformations 
typically use common Pd salts such as Pd(OAc)2 or allyl2PdCl2 
in high concentrations, which are not practical for in vivo 
applications. Encapsulating Pd catalysts has been shown to 
improve biocompatibility, thus Rotello, for example, showed the 
encapsulation of a homogeneous Pd catalyst on the surface of 
gold nanoparticles and their ability to intracellularly activate a 
prodrug of the anticancer drug 5-fluorouracil.[19] Heterogeneous 
Pd nanoparticles embedded in polymers have been used 
successfully in the intra- and extracellular activation of caged 
fluorophores, as well as Pd catalyzed prodrug activation via 
depropargylation reactions and anticancer drug synthesis via 
Suzuki–Miyaura cross-coupling.[20–23] Intracellular activation of 
anticancer prodrugs via Pd catalyzed chemistries requires the 
catalysts to be actively targeted. There are a number of possible 
targeting scenarios, such as the addition of targeting ligands to 
the catalyst, thereby enhancing catalyst uptake and tumor 
specificity,[24] which in combination with a dual and orthogonal 
Pd catalyzed prodrug activation would be a step toward potential 
in vivo applicability.  
Herein, we report the synthesis of a targeted, 
multifunctional Pd catalyst, composed of palladium nanoparticle 
functionalized fluorescent microspheres (PdNP) decorated with 
the cyclic-RGD cancer targeting functionality (cRGDfE-PdNP). 
For validation, we show their catalytic activity by the intracellular 
activation of a profluorophore, but then excitingly the 
simultaneous generation of two anticancer drugs via two 
different Pd catalyzed reactions (decaging and synthesis) inside 
mammalian cancer cells, thus fully exploiting the potential of 
these Pd catalysts. 
 
We have demonstrated that Pd nanoparticles entrapped within 
polystyrene microspheres are able to enter cells and perform Pd 
mediated reactions.[20,25] Here, we used fluorescent 
microspheres (207.7 ± 5.9 nm) loaded with Pd nanoparticles (8.3 
± 1.7 nm, see Fig. 1), conjugated to a targeting ligand. 
 
Scheme 1. c(RGDfE)-Doc-OH modified Pd-functionalised fluorescent 
microspheres (cRGDfE-PdNP). Functionalisation of fluorescent microspheres 
with Pd nanoparticles, followed by cross-linking and Pd entrapment with 
Fmoc-Glu(Cl)-Cl, Fmoc deprotection and cRGDfE-Doc-OH conjugation. 
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The cyclic peptide cRGD is a potent antagonist of the αvβ3 
receptor[26,27] that plays an important role in angiogenesis and is 
overexpressed in many tumors and tumor vasculature, and has 
been used extensively as a targeting ligand.[28–32] Here, the 
optimized cyclic RGDfE moiety, functionalized with a 
dioxaoctanoic acid (Doc) spacer, was used as the targeting 
vector (Supporting Scheme S1). This was introduced via 
coupling of the side-chain protected peptide c[R(Pbf)GD(tBu)fE]-
Doc-OH (see Supporting Scheme S2) to amino groups on the 
surface of the fluorescent Pd-loaded particles, with subsequent 
side-chain protecting group removal with 0.1 M HCl in HFIP, to 
give the targeting Pd-functionalized particles cRGDfE-PdNP 
(Fig. 1, Supporting Scheme S2). Cellular uptake of the 
fluorescent particles (cRGDfE-PdNP) was evaluated on the αvβ3-
positive human glioblastoma cell line U87-MG and the αvβ3-
negative human breast adenocarcinoma cell line MCF-7. The 
receptor-positive cell line showed >95 % uptake after 1 h, 
whereas <4 % of receptor-negative cells showed uptake (as 
analyzed by flow cytometry, Fig. 2). The intracellular location of 
the particles in U87-MG cells was determined by incubating with 
cRGDfE-PdNP for 30 min, with fluorescence microscopy 
imaging showing that the particles had localized into early 
endosomes (Fig. 2). A competition assay with the peptide 
c(RGDfE)-OH corroborated that uptake was due to receptor-
mediated endocytosis, thus, when U87-MG cells were pre-
incubated with c(RGDfE)-OH (0.1–10 µM for 30 min), flow 
cytometry analysis showed a decrease in cRGDfE-PdNP uptake 
(Supporting Fig. S2). The catalytic activity of the cRGDfE-PdNP 
was explored by the deprotection of non-fluorescent 
propargylcarbamate-protected cresyl-violet 1 (Fig. 3) to form 2 
(λex/em = 583/622 nm, Supporting Fig. S3), with >6–fold increase 
 
Figure 1. Cellular uptake of c(RGDfE)-Doc-OH modified Pd-functionalized 
fluorescent microspheres (cRGDfE-PdNP). (a) Flow cytograms of αvβ3-
negative MCF-7 cells (left) and αvβ3-positive U87-MG cells (right) after 
incubation with cRGDfE-PdNP (50 µg/mL) for 1 h. (b) U87-MG cells were 
incubated with cRGDfE-PdNP (50 µg/mL) and an RFP-tagged endosomal 
stain (CellLight® Early Endosomes-RFP, BacMam 2.0) for 18 h, washed with 
PBS, incubated with the nuclei stain Hoechst 33342 for 10 min and imaged by 
confocal fluorescence microscopy. Panels show (i) cRGDfE-PdNP (green) and 
nuclei (blue), (ii) early endosomes (red) and nuclei (blue), and (iii) merged 
image (orange indicates co-localization of cRGDfE-PdNP in endosomes). 
 
Figure 2. Pd catalyzed fluorescence “switch-on” of 1. (a) The Pd catalyzed 
decaging of 1 via deprotection of the two propargylcarbamate groups to give 2 
(λex/em = 583/622 nm). (b) U87-MG cells incubated with cRGDfE-PdNP (50 
µg/mL, 0.2 µM Pd) for 30 min, washed with PBS, incubated with 1 (20 µM) and 
mean fluorescence intensity (λex/em = 594/660 nm) of cell population analyzed 
by flow cytometry at different time points (n = 3) . (c) Flow cytograms of (i) 
untreated U87-MG cells (control), (ii) cells incubated with cRGDfE-PdNP (50 
µg/mL, 0.2 µM Pd) for 1 h, (iii) cells incubated with 1 (20 µM) for 6 h, and (iv) 
cells incubated with cRGDfE-PdNP (50 µg/mL, 0.2 µM Pd) for 1 h, washed, 
and then incubated with 1 (20 µM) for 6 h. (d) Fluorescence microscopy 
images of U87-MG cells incubated as above. Cells were washed and stained 
with Hoechst 33342 for 10 min. Panels show from left to right: cRGDfE-PdNP 
(green) and nuclei (blue), 2 (red) generated via Pd catalyzed chemistry and 
nuclei (blue), and merged images). 
 
in fluorescence at 37 °C after 18 h (Supporting Fig. S4). 
cRGDfE-PdNP were able to activate 1 in a cell-based assay, 
when U87-MG cells were incubated with the catalysts for 60 min, 
and subsequently incubated with 1, flow cytometry analysis 
showed an uptake of cRGDfE-PdNP (FITC emission filter 
530/30 nm) by >95 % of the cell population, as well as 
fluorescence emission due to the formation of 2 (emission filter 
660/20 nm) after 1 h, with a maximum increase in fluorescence 
observed after 6 h (Fig. 3). The synthesis of 2 was also verified 
by live cell fluorescence microscopy. These results show that 
sufficient particles had escaped the endosomes and were 
catalytically competent. The targeted Pd catalyst was then used 
to synthesize two different anticancer agents inside cells. 5-
Fluorouracil (5FU) 3 is used in clinic and exhibits its anticancer 
activity by inhibition of thymidylate synthase and incorporation of 
its metabolites into RNA and DNA. 5FU is generally given in 
combination with other chemotherapies, enhancing the 
therapeutic effect greatly.[33–35] 






Figure 3. Pd catalyzed synthesis of anticancer agents 5FU 4 and PP-121 7. 
(a) Pd catalyzed deprotection of 3 to give 5FU 4. (b) Suzuki-Miyaura cross-
coupling of 5 and 6 to give anticancer agent PP-121 7. (c) Cell viability of U87-
MG cells treated with compounds 3 and 4 for 5 d at 0 µM to 500 µM (MTT 
assay, n = 3). (d) Cell viability of U87-MG cells treated with compounds 5, 6, 
and 7 for 5 d at 0 µM to 10 µM (MTT assay, n = 3).  
 
Palladium-labile prodrugs of 5FU, for example 5-fluoro-1-
propargyl uracil (Pro-5FU) 4 (Fig. 4), have been used 
successfully in Pd mediated prodrug activation.[19,21] The 
cytotoxic agent PP-121 7 binds to tyrosine kinases (VEGF 
receptor) and inhibits phosphatidylinositol-3-OH kinases (mTOR), 
resulting in anticancer activity towards anaplastic thyroid 
carcinoma[36,37] and can be prepared synthetically from two 
building blocks via Suzuki–Miyaura cross-coupling chemistry 
(Fig. 3).[22] Here, we employed targeted cRGDfE-PdNP to allow 
localized and site-specific intracellular activation; enabling the 
simultaneous decaging of Pro-5FU and a Suzuki-Miyaura cross-
coupling reaction to form PP-121, thus giving an increased 
cytotoxicity profile (Fig. 4).  
Under physiological conditions and in presence of cRGDfE-
PdNP, Pro-5FU 3 was converted to toxic 5FU 4 by Pd catalyzed 
cleavage of the propargyl group with full conversion to 4 after 24 
h (see Supporting Fig. S5), while the anticancer agent PP-121 7 
was synthesized from the non-toxic precursors 5 and 6 via a Pd 
catalyzed Suzuki–Miyaura cross-coupling with 59 ± 2% 
conversion to 7 after 24 h (see Supporting Fig. S6). 
Simultaneous incubation of 3, 5, and 6 in the presence of 
cRGDfE-PdNP in PBS at 37 °C generated 4 and 7 (74 ± 6% and 
37 ± 3% conversion, respectively, by HPLC analysis) after 24 h 
(see Supporting Fig. S7), with the protodeboronation of boronic 
ester 6 observed as a minor side product (15% of 6, Supporting 
Fig. S7). This dual prodrug activation/drug synthesis was 
evaluated in a cell-based assay. Prodrug 3 showed no 
cytotoxicity up to 50 µM and PP-121 precursors 5 and 6 were 
non cytotoxic up to 10 µM (Fig. 4).  U87-MG cells were 
incubated with cRGDfE-PdNP for 1 h, washed to remove any 
extracellular Pd, and incubated with a solution of either prodrug 
3, precursors 5 and 6, or a mixture of 3, 5, and 6. Control cells 
incubated only with cRGDfE-PdNP, the individual precursors, or 
the combined precursors showed no decrease in cell viability. 
When combining the catalysts and the precursors, cell viability 
decreased to 66 % after 5 d when incubated only with 3, and to 
44 % when incubated with precursors 5 and 6, whereas in the  
 
Figure 4. Pd catalyzed activation and synthesis of two anticancer agents. (a) 
Simultaneous decaging of 3 and Suzuki-Miyaura cross-coupling reaction of 5 
and 6. (b) Cell viability of U87-MG cells treated with cRGDfE-PdNP (50 µg/mL, 
0.2 µM Pd) for 1 h, washed, and treated with 3 (20 µM), 5 (4 µM), and 6 (10 
µM) for 5 d (MTT assay, n = 3). *** P<0.001 by one-way ANOVA with Dunnett 
post-test, compared to the untreated control group. 
 
dual reaction (incubating with 3, 5, and 6) cell viability decreased 
to 22 % after 5 d (Fig. 5 and Supporting Fig. S8), demonstrating 
an increase in therapeutic effect when combining the 
deprotection with the Suzuki-Miyaura cross-coupling reaction.  
In conclusion, cRGDfE-functionalized Pd microspheres 
demonstrated rapid and selective uptake in glioblastoma cells, 
while demonstrating the ability to activate a profluorophore 
intracellularly via Pd catalyzed deprotection. The targeted 
catalyst successfully catalyzed the synthesis of the anticancer 
agent PP-121 via a Suzuki-Miyaura cross-coupling of two benign 
precursors, while simultaneously activating a prodrug of 5FU 
inside glioblastoma cells, resulting in an increase in cell death 
compared to the individual treatments. In this therapeutic 
approach healthy cells accumulating the non-toxic drug 
precursors will not experience any effect of the drugs, whereas 
only in cancerous cells, in the presence of the Pd catalysts, will 
the active drugs be formed. This platform, combining dual drug 
synthesis with tumor specificity of the catalysts, is a step forward 
to potential in vivo transition metal catalyzed prodrug therapy.   
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Targeted catalysts: Biocompatible 
Pd catalysts were actively targeted to 
brain cancer cells and, upon 
internalisation, catalyzed the synthesis 
of two anticancer drugs 
simultaneously via a Suzuki-Miyaura 
cross-coupling reaction of two benign 
components and via the decaging of a 
protected prodrug, leading to cell 
death. 
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